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Abstract
Background: Drug regulatory agencies (DRA) support prescription of generic products of intravenous antibiotics assuming
therapeutic equivalence from pharmaceutical equivalence. Recent reports of deaths associated with generic heparin and
metoprolol have raised concerns about the efficacy and safety of DRA-approved drugs.
Methodology/Principal Findings: To challenge the assumption that pharmaceutical equivalence predicts therapeutic
equivalence, we determined in vitro and in vivo the efficacy of the innovator product and 20 pharmaceutically equivalent
generics of gentamicin. The data showed that, while only 1 generic product failed in vitro (MIC=45.3 vs. 0.7 mg/L, P,0.05),
10 products (including gentamicin reference powder) failed in vivo against E. coli due to significantly inferior efficacy
(Emax=4.81 to 5.32 vs. 5.99 log10 CFU/g, P#0.043). Although the design lacked power to detect differences in survival after
thigh infection with P. aeruginosa, dissemination to vital organs was significantly higher in animals treated with generic
gentamicin despite 4 days of maximally effective treatment.
Conclusion: Pharmaceutical equivalence does not predict therapeutic equivalence of generic gentamicin. Stricter criteria
based on solid experimental evidence should be required before approval for human use.
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Introduction
There has been a dramatic increase in clinical use of generic
medicines since 1980, but there are not systematic evaluations of
their therapeutic efficacy compared with innovator products [1,2].
Although essential to reduce health budget costs and to promote
pharmaceutical competition and employment, generic drugs
remain a topic of intense controversy as a result of the accelerated
approval process for human use (which some disagree with), and
sporadic reports of failures and deaths associated with their use
[3–5]. There is an unsurpassable point in this controversy: forcing
the manufacturers of generic drugs to go through the same process
required to bring innovator drugs to market implies a cost overrun
calculated in 150 to 800 million dollars that would hinder their
mainstay objective, i.e., ‘‘to regulate and reduce the medicine’s
price’’ [6]. The solution has been a very short, straightforward and
inexpensive process created to approve generic versions of
innovator products, which requires no comparative preclinical or
clinical safety and/or efficacy studies, hoping that generics would
generate results similar to those obtained with the innovator drug
[7]. In consequence, therapeutic equivalence is assumed after
demonstration of pharmaceutical equivalence and bioequivalence
with respect to a gold standard, usually the innovator [8–10].
Furthermore, only the active pharmaceutical ingredient (API) is
considered responsible for pharmaceutical equivalence, without
special attention to binders, diluents, excipients (fillers), impurities,
and contaminants present in all formulations that may vary widely
between generics and innovators affecting safety and efficacy
[3,11–13]. Of note, drug regulatory agencies (DRA) waive the
requirement of bioequivalence for pharmaceutically equivalent
intravenous solutions because their bioavailability is considered
‘‘self-evident’’ [14].
Aminoglycosides are concentration-dependent, highly bacte-
ricidal antibiotics that act mainly by inhibition of protein
synthesis [15]. In many countries, gentamicin is the compound
most frequently prescribed from this group to treat infections as
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10744serious as peritonitis, pyelonephritis, bacteremia, and endocar-
ditis. Thus, a high number of generic versions are approved for
clinical use, invariably without demonstration of in vivo efficacy
or safety.
To find out if pharmaceutical equivalence is an adequate
surrogate of therapeutic equivalence, we determined with the
neutropenic mouse thigh infection model three pharmacody-
namic outcomes (bactericidal efficacy, prevention of bacterial
dissemination to distant vital organs, and toxicity), comparing
19 pharmaceutically equivalent generic products and the
reference powder against the innovator of gentamicin.
Significant inferiority in any of these endpoints was




The Animal Experimentation Ethics Committee of University
of Antioquia approved and verified the fulfillment of the
institutional policies.
Bacteria and media
Escherichia coli SIG-1, a clinical strain, was the microorganism
inoculated in the neutropenic mouse thigh infection model for all
experiments with a microbiological endpoint (24 hours duration),
and Pseudomonas aeruginosa GRP-0019, a fully-susceptible catheter
isolate, for dissemination studies in the survival model (4 days
long). The quality control organism for all susceptibility tests was
P. aeruginosa ATCC 27853, as recommended by Clinical and
Laboratory Standards Institute (CLSI) [17]. All bacteria were
harvested in cation-adjusted Mueller-Hinton broth and agar for
susceptibility tests and in trypticase soy broth and agar (Becton
Dickinson, Sparks, MD) for in vivo studies. Trypticase soy agar
supplemented with 5% sheep blood was used to recover the strains
from ultra-freezing.
Antimicrobial agents
All intravenous antibiotics were bought from reputable local
drugstores and handled as instructed by the manufacturer.
The innovator’s brand-name was GaramicinaH (GNT-S
Plough, Schering-Plough SA, Bogota, Colombia) [18], and it
was included in every experiment (in vitro and in vivo) to
compare simultaneously with one or more generic products.
The reference powder (not designed for human use) was
imported directly from Sigma Aldrich (St Louis, MO, USA),
and made part of the design as if it were a generic product.
The study was designed to discriminate if generic failure in
vivo was an isolated quality problem (one batch) or a constant
phenomenon (any batch) independent of ‘‘quality’’ as it is
understood by DRA worldwide. We divided generic products
at random in two groups: Batch Group 1 had 10 products
that were allocated to use the same batch for in vitro
susceptibility testing and in vivo determination of efficacy, and
Batch Group 2 had the remaining 10 products allocated to
use different batches in vitro than in vivo. If generic failure
was an incidental phenomenon, we should find a statistically
significant difference (two-tailed Fisher’s exact test) between
Batch Groups 1 and 2 in terms of the number of products
failing in vivo within each group. Table S1 details all products
included in the study, their presentation, license number,
maker, distributor, and the distribution of their batches for in
vivo, in vitro, or both kinds of experiments.
Susceptibility testing
Duplicates of minimal inhibitory (MIC) and bactericidal (MBC)
concentrations of all products were determined twice (generics) or
thrice (innovator product) by broth microdilution following CLSI
methods [19]. GNT-Recipe was not commercially available when
susceptibility testing was done, but one of GNT-Recipe batches
(009040) from the same maker (Vitrofarma S.A.) and with the
same license number (M-006660) was being distributed at the time
as GNT-AZ pharma and was used for MIC and MBC
determinations.
Induction of neutropenia
Six-week-old, 23–27 g, female mice of the strain
Udea:ICR[CD-1] were bred and housed in a murine pathogen-
free barrier facility (Micro-Isolator System, Lab Products Inc.,
Seaford, DE, USA) with free access to sterile water plus vitamin
K3 (Sigma-Aldrich Corp., St. Louis, MO, USA) and autoclaved
mouse feed (Zeigler Bros. Inc., Gardners, PA, USA). Profound
neutropenia (,10 neutrophils/mm
3) was induced by injecting two
doses of cyclophosphamide (CytoxanH, Bristol-Myers Squibb,
Mayaguez, Puerto Rico, USA) intraperitoneally 4 days (150 mg/
kg) and 1 day (100 mg/kg) before infection [20].
Induction of infection
Bacteria were resuscitated from ultra-freezing and grown in two
steps to reach log-phase until OD580 = 0.3 (Spectro 22H,
Labomed Inc., Culver City, CA, USA). Depending on the
infecting microorganism, 10
6 (E. coli)o r1 0
4 (P. aeruginosa) CFU
contained in 0.1 mL were injected into each thigh of anesthetized
mice. The lower inoculum with P. aeruginosa was necessary to
prevent premature death (before 12 hours) in the survival
experiments, designed for a longer follow-up (4 days).
In vivo pharmacodynamics (microbiological endpoint)
Neutropenic mice infected with E. coli SIG-1 were treated
during 24 hours (h) using at least 5 total doses (TD) per product
ranging from no effect (0.75) to maximum effect (768 mg/kg per
day). Each TD was given to subgroups of 2 mice starting 2 h after
inoculation (hour 0 for the model) and divided every 6 h (q6h) in
0.2-mL subcutaneous injections to optimize Cmax/MIC and
AUC/MIC, the pharmacodynamic (PD) indices associated with
efficacy in mice and humans with normal renal function [21,22].
Untreated control mice were sacrificed for bacterial count at 3
time-points: just after inoculation (22h), at the onset (0h), and at
the end of therapy (24h). Treated mice were sacrificed at 24 h and
their thighs dissected under aseptic technique, homogenized
independently to a final volume of 10 mL of saline, serially
diluted, plated and incubated at 37uC for 18 h under air
atmosphere. The limit of detection was 100 CFU/thigh. Bacterial
counts were stored in an Excel database (Microsoft, Seattle, WA)
for subsequent analysis.
Systemic bacterial dissemination and survival
experiments (clinical endpoint)
To test if therapeutic inequivalence affects generics’ ability to
stop bacterial dissemination and eventually impact survival, we
designed an experiment using 35 neutropenic mice randomly
distributed in 3 groups: (1) infected with P. aeruginosa GRP-0019 in
both thighs and mock-treated with sterile saline injections (survival
controls, n=5); (2) infected and treated (experimental group,
n=10 per product); and (3) non-infected but treated (toxicity
controls, n=5 per product). Treatment started either 2 (early) or
6 h (delayed treatment) after infection and consisted of generic
Generic Gentamicin Failure
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gentamicin (GNT-S Plough) during 4 days, 768 mg/kg daily
divided q6h in 0.2-mL subcutaneous injections. At the end, thighs,
lungs, spleen and kidneys were aseptically removed and indepen-
dently homogenized, diluted, plated, and incubated at 37uC for
18 h. In case of acute neuromuscular blockade after gentamicin
injection, affected mice were treated with calcium gluconate
(130 mg/kg), 1 to 3 subcutaneous doses until obtaining clinical
response [23,24]. Although calcium concentrations affect MIC
and MBC determinations of aminoglycosides and these induce
renal excretion of calcium, there is no evidence that calcium affects
aminoglycoside pharmacokinetics or pharmacodynamics in vivo
[25].
Statistical analysis
For in vitro efficacy, the significance of the difference between
geometric means of MIC and MBC was calculated with
Kruskal-Wallis followed by Dunn’s test (StatXact-5H,C y t e l
Software Corp., Cambridge, MA) [26]. The validation of a
microbiological method to demonstrate the pharmaceutical
equivalence of generic products of gentamicin is described
thoroughly elsewhere [25]. The slopes and intercepts of
concentration-response curves from each generic were com-
pared against the innovator with the overall test for coincidence
of regression lines.
For in vivo data, we calculated net antibacterial effect (E,
dependent variable) of each product’s dose (D, independent
variable) by subtracting the number of CFU/g of untreated
controls (hour 24) from CFU/g remaining in mice treated
during 24 h (for this model, 1 thigh weighs 1 g). As E implies
bacterial killing, it is a negative number, except under ineffective
doses that eventually allow growth beyond that of untreated
controls.
Least-squares nonlinear regression (NLR) was used to generate
the sigmoid dose-response relationship typical of bactericidal





50 zDN    ; E is the effect (dependent variable), D is the
24h total dose (independent variable), Emax is the maximum effect
and quantifies efficacy (the most important PD parameter), ED50 is
the dose yielding half the Emax (a PD parameter measuring the
drug’s approximate potency), and N is the Hill’s slope, the PD
parameterdescribingtheaffinitybetween adruganditstarget.Inthe
system used here (the neutropenic mouse thigh infection model), N
represents the steepness of the curve and reflects, although
indirectly, the ability of the API to bind a specific molecular target
[27]. These three are the primary PD parameters, all derived from
the Hill’s model (SigmaPlot 11.0H, SPSS Inc., Chicago, IL).
We also computed the doses (mg/kg per day) required in vivo to
reach a net bacteriostatic effect (BD) and to kill the first, second
and third logs of bacteria (1LKD, 2LKD and 3LKD respectively).
These secondary PD parameters determine the exact potency of the
antibiotic, and portray more clinical significance than ED50
because their magnitudes are corrected by the net bacterial growth
(G) calculated from the number of microorganisms (CFU/g)
growing in untreated controls (24h minus 0h) during the time of
the experiment [22,28]. Secondary PD parameters are expressed





































































The magnitude of significant primary and secondary PD
parameters obtained for each generic product and the reference
powder were compared with those obtained for the innovator by
the overall test for coincidence of the NLR, a specialized statistical
technique for Curve Fitting Analysis (CFA) (Prism 5.0, GraphPad
Software, Inc., San Diego, CA) [29].
We used log-rank test for analysis of survival experiments and
the Fisher’s exact test followed by Bonferroni’s inequality
correction to determine differences between generic and innovator
gentamicin to prevent bacterial dissemination to organs away from
the infection site.
Although efficacy and bacterial dissemination were respectively
the microbiological and clinical end-points of pharmacodynamic
experiments, we also compared survival rate and frequency of
adverse events despite the fact that the design had very low
statistical power due to ethical considerations (i.e., to employ de
minimum number of animals strictly necessary to demonstrate the
principal endpoints). Thus, for the microbiological end-point (in
vivo efficacy), accepting a 5% chance for a type I error (a-error)
and expecting residuals’ standard deviations ,0.5 logs, the
treatment of 10 animals per product to compare 20 generics
(ANOVA) with the innovator confers 74% power to reject the null
hypothesis (H0: generics = innovator product) if the magnitude of
the difference in antibacterial efficacy is .1 log10 CFU/g.
Likewise, for the clinical end-point (bacterial dissemination),
accepting a=0.05 and using a control to experimental subjects
ratio of 0.5, a difference between generic and innovator of at least
66% (in protection from bacterial dissemination respect to
untreated mice) would be necessary to assure 80% power [30].
For survival endpoints in experiments where treatment started 6 h
post-infection and accepting a=0.05, the use of 10 subjects per
arm with an accrual interval of 3 h, an additional follow-up after
the accrual interval of 96 h, a median survival time of 60 h for the
arm treated with innovator, and a median survival time of 50 h for
the arm treated with the generic, will confer only 6.2% power to
detect differences in survival rate between both arms. For
experiments where treatment started 2 h post-infection the
median survival time of treated mice is not computable because
mortality is far less than 50% (based on pilot experiments). Despite
these obvious limitations in power, survival experiments with this
design were approved and executed because pilot tests strongly
suggested that using dissemination as their principal endpoint
could generate enough power to demonstrate significant differ-
ences between both products.
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Antimicrobial agents
Seventeen of 21 products (81%) including the innovator were
produced in Colombia (Table S1). One generic and the reference
powder were made in USA; other 2 generic products were
manufactured in Germany and Austria. It should be noted that
Vitrofarma S.A. and Viteco S.A. (both from Bogota, Colombia)
manufactured 7 (37%) and 5 (26%) of 19 generic products,
respectively. We included all these products despite coming from
the same maker because they were commercialized by different
distributors and under different names. The results and conclu-
sions of the study were not influenced at all by the preponderance
of these two makers in the sample.
Susceptibility testing
MIC and MBC (geometric mean and range) of each generic
product, the reference powder and the innovator against E. coli
SIG-1 or P. aeruginosa ATCC 27853 (quality control strain) are
shown in Table 1. Statistically significant differences were
observed only for generic GNT-AZ pharma (batch 009040),
which displayed very high MIC and MBC (45.25 and 64 mg/L,
respectively) compared with the innovator (0.71 and 0.79 mg/L,
respectively, P,0.05 in both cases). The MBC to MIC ratio of this
product remained undistinguishable from the innovator
(P=0.347). This batch of GNT-AZ pharma was studied in the
animal model under the name GNT-Recipe.
MICs, MBCs and MBC/MIC ratios of all other gentamicin
generic products against E. coli were not different to those of the
innovator (Table 1). Quality control results with P. aeruginosa and
innovator gentamicin were always located within the range
accepted by CLSI (0.25–4 mg/L).
Pharmaceutical equivalence
Generic products of gentamicin had in vitro the same potency
and concentration of the innovator, i.e., they were all pharma-
ceutical equivalents. Details of these data can be seen in a previous
publication [25]. GNT-Anglopharma, GNT-Merck, GNT-Rande,
and GNT-Servipharma were not available at the time of these
tests. Batch 009040 (GNT-AZ pharma and GNT-Recipe) was not
available either, but other batches from both distributors were





9.44–9.68 CFU per thigh before
starting and after ending therapy, respectively (net growth range of
E. coli SIG-1 = 2.00–2.26 log10 CFU/g in 24 h). No significant
variation in net growth was observed between untreated controls
along all the experiments performed (P=0.415). Figure 1 shows
the reproducibility of the animal model; for this, we compared the
pharmacodynamic profiles derived from three non-linear regres-
sions computed for the innovator product when we used the same
Table 1. Minimal inhibitory (MIC) and bactericidal (MBC) concentrations (geometric mean and range) and MBC/MIC ratios of 19
generic products of gentamicin (GNT), the reference powder, and the innovator against E. coli SIG-1 (clinical strain) and P.
aeruginosa ATCC 27853 (control strain) by standard broth microdilution techniques.
Escherichia coli SIG-1 Pseudomonas aeruginosa ATCC 27853
GNT Product MIC (mg/L) MBC (mg/L) MIC (mg/L) MBC (mg/L)
Mean Min Max Mean Min Max Mean Min Max Mean Min Max
S Plough 0.71 0.50 1.00 0.79 0.50 2.00 1.26 0.50 4.00 2.52 1.00 8.00
Abbott 0.84 0.50 1.00 2.00 1.00 4.00 1.19 1.00 2.00 4.76 4.00 8.00
Anglopharma 0.84 0.50 2.00 1.41 0.50 4.00 1.41 1.00 2.00 3.36 2.00 8.00
Az pharma* 45.25 32.0 64.0 64.00 64.0 64.0 45.25 32.0 64.0 64.00 64.0 64.00
Biochemie 1.19 0.50 2.00 1.41 1.00 2.00 1.19 1.00 2.00 4.00 2.00 8.00
Biogenta 0.59 0.25 1.00 1.00 0.50 2.00 1.19 1.00 2.00 4.00 2.00 8.00
Colmed 0.59 0.50 1.00 1.19 0.50 4.00 0.84 0.50 1.00 2.83 2.00 8.00
Gencol 0.84 0.50 2.00 1.00 0.50 4.00 1.41 1.00 2.00 4.76 2.00 16.00
Genfar 1.00 0.50 2.00 1.68 0.50 4.00 2.00 2.00 2.00 4.00 4.00 4.00
Lab America 1.19 1.00 2.00 2.00 1.00 4.00 1.68 1.00 2.00 4.76 2.00 8.00
Labinco 1.00 0.50 2.00 1.41 1.00 2.00 1.41 1.00 2.00 4.76 2.00 8.00
La Sante 0.71 0.50 1.00 1.00 0.50 2.00 1.00 1.00 1.00 4.76 2.00 8.00
Memphis 1.19 0.50 2.00 1.68 0.50 4.00 1.19 0.50 2.00 3.36 2.00 4.00
Merck 0.84 0.50 2.00 0.84 0.50 2.00 1.41 1.00 2.00 2.83 2.00 4.00
MK 0.59 0.50 1.00 0.71 0.50 2.00 1.19 1.00 2.00 2.00 2.00 2.00
Ophalac 1.00 0.50 2.00 2.83 2.00 4.00 1.68 1.00 2.00 4.76 4.00 8.00
Pentacoop 1.19 0.50 2.00 2.00 1.00 4.00 2.00 2.00 2.00 4.76 4.00 8.00
Rande 1.19 0.50 2.00 1.68 1.00 2.00 1.41 1.00 2.00 4.00 2.00 8.00
Servipharm 1.41 1.00 2.00 4.00 2.00 8.00 1.41 1.00 2.00 4.00 2.00 8.00
Sigma 0.56 0.25 1.00 0.79 0.25 2.00 1.00 1.00 1.00 2.25 1.00 4.00
*P-value ,0.05 by Dunn’s multiple comparison test. This product (GNT-AZ pharma batch 009040) was commercialized later as GNT-Recipe (batch 009040) and therefore
tested in the animal model, failing that test too.
doi:10.1371/journal.pone.0010744.t001
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day 2, P=0.0573; panel A), or different batches (between-batch
variation, CB1DPDC2 in day 2 versus CB3AMKB04 in day 3,
P=0.2444; panel B), or all batches from GNT-S Plough studied in
vivo (P=0.0573; panel C).
Reproducibility of the animal model was also evident in its
capacity to consistently detect generic failure independently of the
product or batch involved. Table 2 shows that there was no
difference (P=0.6563 by Fisher’s exact test) between Batch
Groups 1 and 2, demonstrating that in vivo failure of generic
products of gentamicin was detected the same if one batch was
tested in vivo and vitro (60% failed) or if different batches were
used in each test (40% failed). Table 2 also shows that in vitro
testing is not sensible to detect absence of therapeutic equivalence
(despite duplicate broth microdilution assays repeated two of three
times), while the animal model was able to detect the only product
that failed in vitro (batch 009040 from GNT-AZ pharma and
GNT-Recipe) plus all others that were indistinguishable by
conventional MIC and MBC testing.
Table 3 shows primary (Emax,E D 50, N) and secondary (BD,
1LKD, 2LKD, 3LKD) pharmacodynamic parameters of all
generics compared with the innovator. All gentamicin products
fitted Hill’s model, which described their dose-effect relationships
with an excellent fit, generating multicollinearity-free, highly
significant PD parameters, and a nonlinear regression fulfilling the
assumptions of normality, constant variance and independence
(Table 3).
From 20 generic products, 10 had PD profiles not significantly
different from the innovator (Fig. 2, panel A) and 10 (including the
reference powder) displayed significantly lower efficacy (Fig. 2,
panel B), killing approximately 1 million less bacteria per gram of
tissue than the innovator. In vivo failure happened independently
of the maker (or its prestige), the vendor, the country of
manufacture, pharmaceutical equivalence, or MBC and MIC
identity with GNT-S Plough. Figure 3 illustrates the highly
significant difference (P,0.0001) in PD profiles of two generics
from very well reputed makers, one destined to clinical use (GNT-
Abbott) and the other to experimental use (GNT-Sigma), with
GNT-S Plough; all three products had the same batch studied in
vitro and in vivo, illustrating how pharmaceutical equivalence
cannot predict therapeutic equivalence.
In vivo potency was computed in the form of primary (ED50)
and secondary PD parameters because it is a reliable estimate of
the dose required in vivo to reach specific endpoints, such as
bacteriostasis (BD) or bactericidal effect of one (1LKD) or more
(2LKD, 3LKD) logs of microorganisms per gram of tissue. GNT-S
Plough, for example, demonstrated no difference in potency along
all experiments: as expected when there are no differences in the
comparison of the complete nonlinear regression curves (Figure 1,
panel C), ED50 was indistinguishable within or between lots of
GNT-S Plough (ED506SEM: batch CB1DPDC2 in day 1 =
53.762.9, batch CB1DPDC2 in day 2 = 96.5638.1, batch
CB3AMKB04 in day 3 = 48.067.5 mg/kg per day; P=0.0640
by CFA). Although 6 of 10 failing products appear more potent
than the innovator under simple NLR (Table 3), in all cases it is a
false impression given by their lack of bactericidal efficacy.
Multiple NLR (Table 4) allows computation of ED50 and N for
each product assuming that the null hypothesis is correct, i.e., that
all generics are as effective as the innovator. For example GNT-
Abbott (Table 3), a less effective but apparently more potent
generic, was in fact not more potent when required to reach the
innovator’s efficacy under multiple NLR (3LKD = 241628.3 vs.
203645.9 mg/kg per day, respectively; P =0.511 by CFA). The
same conclusion was reached when identical analysis was applied
to any other inequivalent product apparently more potent than
GNT-S Plough: GNT-Abbott, GNT-Colmed, GNT-Merck and
GNT-MK, P=0.067 by CFA of ED50.
Hill’s slope (N) is the primary PD parameter that measures the
sensitivity with which a particular system translates the concen-
tration of a drug into an effect; therefore, the highly specific
mechanism of action of gentamicin usually gives N near to 1, just
as we observed with the innovator (N=1.2060.2) or the
therapeutically equivalent generics (N=1.3060.19; P=0.1846
by CFA). In contrast, the 10 products without therapeutic
equivalence exhibited slopes significantly higher than the innova-
tor (1.7360.3; P=0.0261).
Systemic bacterial dissemination and survival
experiments
Figure 4 shows survival rates for infected but untreated mice
(survival controls), infected and treated mice (experimental
group), and non-infected but treated mice (toxicity controls). All
untreated mice died of sepsis between 12 and 18 h after infection,
while most of those receiving early treatment (2 h after infection)
survived the experiment in good health without difference
between generic (80%) and innovator gentamicin (90% survival,
P=0.557).
Figure 1. Repeatability of the animal model to determine therapeutic equivalence of generic gentamicin products. The graphs
illustrate the non-significant differences on the innovator’s pharmacodynamic profiles when a single (within-batch variation, Panel A), or a second
(between-batch variation, Panel B), or multiple lots (total variation, Panel C) are used to treat E. coli SIG-1 in vivo. In all graphs showing data obtained
with the animal model every data-point represents one mouse (mean of two thighs; if standard errors of the mean were to be included, the bars
would not be longer than 0.5 logs).
doi:10.1371/journal.pone.0010744.g001
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survival than early treatment but, again, no differences in survival
were detected between generic (20%) and innovator gentamicin
(30%, P=0.448). Despite this apparent similarity in survival, a
great difference was evident in the capacity of both products to
sterilize the thighs of survivors after 4 days of treatment: 100%
mice in the innovator group had sterile thighs, while 0% achieved
this goal after generic treatment, leaving approximately 4 log10
CFU of P. aeruginosa per thigh. Additional differences were
observed between products in the rate and extent of bacterial
dissemination to different organs (lungs, spleen and kidneys);
treatment with generic gentamicin could not prevent lung
dissemination of P. aeruginosa (80%), a result that was undistin-
guishable from placebo (100% of mice had positive lung cultures,
P=0.5238). The innovator, on the other hand, did protect mice
from lung dissemination (10% positive lung cultures, P=0.0004
compared with generic or placebo treatment by Bonferroni
inequality test). Spleen dissemination was 0%, 40%, and 100%
for innovator, generic, and the untreated control group,
respectively, but the difference between innovator and generic
did not reach statistical significance (P=0.0867). Kidneys
dissemination, as expected from an antibiotic with renal clearance,
was completely prevented by both generic and innovator
gentamicin (Figure 5). Even though acute neuromuscular blockade
was twice as frequent after injection of generic (13 events) than
innovator gentamicin (6 events), it did not reach statistical
significance (P=0.158).
Discussion
Generic substitution for brand-name antibiotics has become an
accepted and widespread practice, and bioequivalence remains the
mainstay criterion to gain the public trust in such strategy. The
methodology for testing generics and the parameters accepted as
proof of bioequivalence have been established by each national
DRA [25,31–33], but all exempt parenteral solutions from
demonstrating this equivalence because it is considered ‘‘self-
evident’’ [25]. Some authors have expressed concerns about this
approach, especially for drugs with narrow therapeutic index, but
no attempt has been done to challenge this dogma [34–36]. Here,
we demonstrated that even pharmaceutically equivalent products
of gentamicin may fail therapeutic equivalence compared with the
innovator in the same animal model used in preclinical studies
[21].
In open contradiction with pharmaceutical equivalence, 53% of 19
generic products and the reference powder (GNT-Sigma) were
devoid of therapeutic equivalence. The magnitude of this inequi-
valence (and its real-life relevance and significance) can be estimated
from the lack of efficacy (all 10) or potency (6 products): ineffective
productskilledpergramoftissue0.77–0.91millionlessbacterialcells,
a n dr e q u i r e d2 . 7 7 6to .3.166greater dose to kill the third log of
bacteria compared with the innovator. This lack of potency is critical
for an aminoglycoside, because we found during standardization of
the survival model that the dose required for maximal efficacy
(768 mg/kg per day) was neurotoxic for the mice if given for more
Table 2. Randomization of generic products in two groups to establish if in vivo failure was incidental (one batch) or constant (any
batch): identification of non-therapeutically equivalent generics is independent of the batches of each product studied in vitro
and/or in vivo.
Generic Product Failure
Batch Group Gentamicin Generic Product In vitro In vivo
1 Abbott No Yes
(same batch tested in vitro and in vivo) Biochemie No Yes
Colmed No Yes
Gencol No Yes






2 Anglopharma No Yes









*This product (AZ pharma batch 009040) was commercialized later as Recipe (batch 009040) and therefore tested in the animal model, failing that test too ({). However,
AZ pharma batches 303030 (in vitro) and 0110059 (in vivo) did not fail; (please see Discussion).
doi:10.1371/journal.pone.0010744.t002
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PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10744than 24 h, and a dose twice that (1536 mg/kg) was lethal. Bacterial
dissemination from the thighs to distant organs like the lungs also
supports the argument in favor of the relevance of the differences
demonstrated by the animal model. Inequivalent generics were not
only incapable of sterilizing (detection limit, 100 CFU/thigh) the site
of infection after 4 daysof treatment at the dose required for maximal
efficacy, but left 100,000 bacterial cells per thigh that disseminated
effectively to the lungs (8-fold compared with the innovator). In burnt
patients, for example, 1000 cells of P. aeruginosa are enough to invade
the skin [37].
Figure 2. In vivo pharmacodynamics. Panels illustrate the dose-response curves derived from the neutropenic mouse thigh infection model of
19 generic products and the reference powder with (A) or without (B) therapeutic equivalence respect to the innovator.
doi:10.1371/journal.pone.0010744.g002
Table 3. In vivo efficacy of 19 generic products, the reference powder and the innovator of gentamicin (simple nonlinear
regression analysis under Hill’s model; all products passed normality and constant variance tests).
Gentamicin Adj. R
2 Emax SE ED50 SE N SE BD SE 1LKD SE 2LKD SE 3LKD SE
P value
(CFA)
S Plough* 0.97 5.99 0.23 55.75 6.44 1.20 0.12 33.77 2.67 59.71 4.45 107.43 9.52 243.05 29.41 NA
Abbott 0.98 5.21 0.11 27.26 2.47 1.99 0.25 22.65 2.02 33.51 2.87 53.62 5.80 NS - 0.001
Anglopharma 0.90 4.81 0.30 27.82 6.92 1.67 0.54 24.03 5.50 40.11 9.80 80.43 28.97 NS - 0.022
AZ pharma 0.98 5.45 0.26 58.04 7.43 1.59 0.29 44.80 4.27 71.43 7.58 122.00 18.18 365.41 141.17 0.187
Biochemie 0.98 4.86 0.15 38.14 4.25 1.42 0.18 31.45 2.99 56.79 5.71 124.69 17.37 NS - 0.001
Biogenta 0.98 6.44 0.42 74.87 13.56 1.06 0.15 40.09 3.44 73.52 6.42 134.31 15.31 285.50 42.63 0.577
Colmed 0.99 5.21 0.13 27.73 2.24 1.82 0.20 21.56 1.63 33.04 2.36 54.00 4.90 165.81 50.94 0.004
Gencol 0.96 5.26 0.37 59.55 11.72 1.43 0.33 45.49 6.29 77.91 12.14 147.38 31.56 NS - 0.043
Genfar 0.99 5.40 0.16 37.49 3.03 1.86 0.26 28.80 2.38 43.17 3.05 67.76 6.40 157.75 33.38 0.144
Lab America 0.98 5.91 0.29 47.33 7.12 1.21 0.17 29.91 3.18 53.00 5.53 96.67 12.68 232.64 44.94 0.814
Labinco 0.99 4.84 0.09 36.07 1.89 2.27 0.26 31.41 1.76 45.48 2.07 73.73 5.42 NS - 0.004
La Sante 0.99 5.71 0.23 43.21 5.08 1.43 0.21 28.82 2.84 47.59 4.35 80.77 9.51 179.79 33.20 0.639
Memphis 0.99 5.55 0.21 52.94 5.47 1.55 0.22 36.76 3.07 59.06 4.80 98.16 10.87 222.54 40.48 0.479
Merck 0.94 5.07 0.23 27.42 5.14 1.61 0.38 21.24 3.75 34.98 6.09 63.30 14.62 NS - 0.025
MK 0.99 5.10 0.14 26.18 2.44 1.66 0.19 20.20 1.67 32.64 2.70 57.52 6.34 NS - 0.004
Ophalac 0.98 6.46 0.63 97.56 29.2 0.93 0.16 45.59 5.69 91.36 11.33 180.73 25.78 416.96 71.50 0.067
Pentacoop 0.98 5.68 0.27 38.50 5.82 1.32 0.21 27.13 3.21 46.59 5.24 84.56 11.25 231.68 50.87 0.258
Rande 0.99 6.02 0.16 46.35 4.09 1.09 0.08 28.32 1.78 52.82 3.08 101.76 6.78 261.75 23.48 0.392
Recipe 0.99 5.32 0.13 48.53 4.28 1.22 0.11 34.62 2.45 64.45 4.59 132.45 12.23 672.49 220.61 0.022
Servipharm 0.97 5.56 0.32 41.25 7.56 1.24 0.22 29.37 3.88 52.94 7.33 103.05 18.76 NS - 0.519
Sigma 0.97 5.07 0.29 72.71 10.94 2.19 0.54 59.49 6.38 85.77 11.95 132.01 25.78 NS - 0.000
*Innovator product; Adj R
2: adjusted coefficient of determination; Emax: maximum effect; SE: standard error; ED50: effective dose to kill 50% of Emax; N: slope; BD:
bacteriostatic dose; 1LKD, 2LKD, 3LKD: 1, 2, or 3 log kill dose, respectively; CFA: curve fitting analysis; NS: parameter value not significantly different from zero.
doi:10.1371/journal.pone.0010744.t003
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(3LKD), altered target-affinity (N), higher frequency of bacterial
dissemination to different organs, and twice more adverse events
(neuromuscular blockade), our experimental design did not have
enough power to detect significant impact on survival: 770 mice
would be necessary per arm to obtain a power of 80% to
demonstrate a difference of 10 h in the median time-to-death.
Translating this situation to clinical practice would imply the
exposure of thousands of patients to demonstrate any difference in
survival after exposure to generic gentamicin, and explains the
absence of therapeutic failures associated with use of ‘‘bioequiv-
alent’’ generics [38]. It does not imply that generic use is devoid of
consequences, it just confirms that mortality is an exceedingly
gross outcome to compare efficacy in vivo. In a recent cohort
study, Ammerlaan et al. found that there are no differences in
efficacy and 30-day mortality rates between inadequate or
adequate therapy for patients with S. aureus bacteremia [39]. We
also believe that these findings reflect that mortality is a very crude
measure to show differences in effectiveness of antibiotic therapy
[40].
The absence of in vitro differences between generics and
innovator confirms that these products were quality-drugs if
judged by current regulations and requirements. Batch 009040
was unique in that it (as GNT-AZ pharma) failed in vitro (MIC
36–646and MBC 25–366higher than GNT-S Plough against P.
aeruginosa and E. coli) and in vivo (as GNT-Recipe), leaving alive
768,000 E. coli cells per gram of tissue in comparison with the
innovator. The other 9 inequivalent generics failed in vivo despite
being equivalent by MIC, MBC, MBC/MIC ratios, concentration
and potency of API, and independently of their origin (generics
imported from Austria, Germany and USA invariable failed
therapeutic equivalence). It is then clear that the majority (90%) of
nonequivalent generics did not have quality problems based on
current regulations, the real problem originates in a systematic
failure to establish true bioequivalence: current tests do not predict
in vivo efficacy, and the term bioequivalence undoubtedly implies
much more than similar pharmacokinetics.
Panels A and C of Figure 1 show that two of three PD profiles of
the innovator almost reach a statistically significant difference
(P=0.0573). The high variance depends on batch CB1DPDC2
Figure 3. Unpredictability of therapeutic equivalence from pharmaceutical equivalence. The graph illustrates the dose-response curves
of gentamicin made by three well-reputed makers: Abbott, Sigma and S. Plough. Abbott and Sigma were indistinguishable from S Plough in terms of
concentration and potency of the active pharmaceutical ingredient, MIC, MBC, MBC/MIC ratios but significantly different in terms of therapeutic
efficacy, although the same batch of each product was tested in vitro and in vivo.
doi:10.1371/journal.pone.0010744.g003
Table 4. Pharmacodynamic parameters obtained by multiple
NLR of 10 generic products of gentamicin with significantly
lower efficacy than the innovator.
GENTAMICIN NORM. CV ED50 SE N SE
S Plough OK OK 55.75 7.56 1.20 0.15
Abbott Failed OK 39.90 6.27 1.08 0.15
Anglopharma OK OK 60.91 13.86 0.80 0.12
Biochemie OK OK 74.35 12.59 0.88 0.10
Colmed OK OK 38.36 5.69 1.20 0.18
Gencol OK OK 79.07 13.24 1.05 0.15
Labinco OK OK 56.37 9.73 1.14 0.19
Merck OK OK 47.34 9.01 0.91 0.12
MK OK OK 40.28 6.72 1.03 0.15
Recipe OK OK 69.51 10.95 0.91 0.10
Sigma OK OK 99.65 14.70 1.25 0.17
Under this analysis, maximum effect (Emax) for all products is fixed to the
innovator’s (Emax=5.99log 10 CFU/g).
Norm: normality test; CV: Constant variance test; ED50: effective dose to kill 50%
of Emax; N: Hill’s slope; SE: standard error.
doi:10.1371/journal.pone.0010744.t004
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and day 2), and is explained by a very high efficacy
(Emax=6.73760.9257 log10 CFU/g) with a large standard error
for that parameter. Since ED50 computation depends on the Emax,
it is also high and with a large error (96.47638.1 mg/kg per day),
and such influence is confirmed by two relatively large variance
inflation factors (9.9941, 7.9508 and 3.2973 for Emax,E D 50 and
N), indicating the presence of a mild multicollinearity between the
first two PD parameters. If gentamicin products are compared
with the innovator using only the dose-response curves obtained
during the experiment in which generic was studied, 3 more
generics would appear failing in vivo, for a total of 13. Our design
is to compare all generics against the NLR of all the data from the
innovator, a less powerful but more reliable strategy in that all the
variance of the data obtained with the innovator is taken into
account. Given that the difference between the individual NLRs of
Figure 4. Results from survival experiments. Log-rank test curves obtained from neutropenic mice infected in the thighs with P. aeruginosa
GRP-0019 and treated during 4 days with placebo (n=5), GNT-Recipe (n=10), or the innovator of gentamicin (n=10) at the dose required for
maximal effect (768 mg/kg per day divided q6h), starting 2 h (panel A) or 6 h (panel B) post-infection. Uninfected neutropenic mice serving as
toxicity controls received the same treatment and were identical to the other animals but, instead of P. aeruginosa, were mock-inoculated in the
thighs with sterile saline (n=5 mice per gentamicin product). No significant impact on survival was detected between both gentamicin products.
doi:10.1371/journal.pone.0010744.g004
Figure 5. Bacterial dissemination to distant vital organs during survival experiments. After the fourth day of treatment (same
experimental design described in Figure 4) the animals that survived were euthanized and their thighs, lungs, spleens and kidneys processed for
bacterial counting (mice found dead were processed immediately). Although thigh counts are not illustrated in the graph, GNT-Recipe left .100,000
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the same population and therefore are better described by a single
dose-response curve, i.e., a significantly more robust and reliable
NLR. It prevents the model from identifying as failures those
generics with borderline differences respect to the comparator
product.
Our results suggest that excipients and impurities play a key role
in efficacy [3,11,13]. GNT-Sigma, the reference powder, is a pure,
analytical-grade product, devoid of excipients (therefore not
intended for clinical use), that displayed pharmaceutical equiva-
lence and similar in vitro activity, but failed in vivo by a large
difference in efficacy compared with the innovator
(Emax=5.0760.29 vs. 5.9960.23 log10 CFU/g, respectively).
GNT-Sigma required greater doses for bacteriostasis and to kill
the first and second logs of bacteria (BD, 1LKD, and 2LKD were
1.766, 1.446, and 1.236greater, respectively), and could not kill
3 logs at maximal effect. Clinical-grade generic products that failed
in vivo displayed the same PD pattern. Under current regulations,
the innovator is required to publish the chemical structure of its
molecule, but not the excipients of its pharmaceutical product
[8,9,14,33]. Only recently, the British, Chinese and United States
pharmacopeias accepted that the presence of these unknown or
unwanted chemicals even in small amounts may influence the
efficacy and safety of the API [12,31,41,42]. This change of policy
might have been precipitated by the recent demonstration of
numerous fatalities (thousands) associated with the use of a
contaminated generic heparin in America, Australia and Europe
[3]. The fact that GNT-Sigma had one of the worst efficacies
despite its high-quality grade, points towards the absolute lack of
excipients as the cause for its ineffectiveness. These results reflect
the importance of excipients for efficacy, and suggest that failure of
generic gentamicin might be related to the use of excipients or the
presence of impurities not present in the innovator product. It is
well-known that excipients are promoters of degradation more
than stabilizers of drug substances, but their role depends on all
factors that may cause the molecular transformation of the drug,
including the interaction between molecules adjacent to the API,
as is often the case with impurities and excipients [43,44]. Then,
suboptimal excipients or impurities may induce changes that
compromise the clinical efficacy and safety (toxicity), especially if
they have the ability to interact and modify the API promoting an
unexpected instability of the generic antibiotic [45–47]. Evidence
in favor of this hypothesis was recently published by Mastoraki et
al, who were intrigued by an unexpectedly high incidence of post-
operative infections following a change from innovator to generic
cefuroxime for surgical prophylaxis of coronary artery bypass
patients. They found that the generic formulation was hydrolyzed
after reconstitution in a much shorter time compared with the
innovator, breaking down into two ineffective parts [5,48].
Aminoglycosides target a conserved region of rRNA sequence
discriminating between prokaryotic and eukaryotic ribosomes.
Their highly specific action is related to the unique presence in
16S rRNA of an A1408?A1493 base pair (E. coli) instead of the
G1408:A1493 base pair on human’s ribosome [49]. The geometry
of the A?A pair is different to the G?A pair, creating a binding
pocket with different affinity for the ring I of aminoglycosides,
more favorable to the interaction of the antibiotic with the
prokaryotic ribosome. According with this, antibiotic resistance
could result from either decreased affinity of the antibiotic for the
ribosome or non-productive binding of the drug to ribosome.
Although we used a fully susceptible strain, some pharmaceutical
equivalent generics failed efficacy, suggesting an alteration in the
affinity or the binding. The greater Hill slopes of inequivalent
generics could suggest the presence of other components like
excipients or impurities interfering with API, reducing its affinity
for or inducing non-productive binding to active ribosomes.
In conclusion, therapeutic equivalence cannot be reliably
predicted from pharmaceutical equivalence of gentamicin generic
products. A thorough revision of current regulations, including the
development and application of appropriate preclinical tests to
determine therapeutic equivalence, should be considered before
approval of generic gentamicin for human or veterinary use.
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